Covid 19 Research using Clinical Trials (Home Page)
Report for D006976: Hypertension, Pulmonary NIH
(Synonyms: Hypertension, Pul, Hypertension, Pulmon, Hypertension, Pulmonary)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002092 | Pulmonary arterial hypertension HPO | 1.00 |
| HP:0000822 | Hypertension HPO | 0.28 |
There is one clinical trial.
Clinical Trials
1 The Prevalence of Pulmonary Hypertension, With or Without Right Ventricular Loading, in Patients With COVID-19 Who Are Being Treated With a Respirator in the Intensive Care Unit.
The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease. As a result, very specific treatment options are missing. The US Medicines Agency (FDA) has in the last days given a general license for treatment with inhaled nitric oxide (iNO). Inhaled NO in Sweden (and Europe) is approved for the indication of pulmonary hypertension in adults. However, no one has yet described the occurrence of pulmonary hypertension, with or without right ventricular loading, in the Covid-19 patients who become so seriously ill that they need to be treated at an IVA ward. Knowledge of this is, of course, a prerequisite for determining the need for pulmonary artery catheterization (PA catheter, Swan-Ganz catheter) and also to better understand whether iNO treatment or other forms of lung selective vasodilation therapy may be of benefit to this patient group.
NCT04459364 Hypertension, Pulmonary Right Ventricular Overload COVID MeSH:Hypertension, Pulmonary Hypertension
HPO:Hypertension Pulmonary arterial hypertension
Primary Outcomes
Description: To determine the prevalence of pulmonary hypertension and right ventricular load in patients with COVID-19 treated in intensive care unit evaluated by routine echocardiography.
Measure: Prevalence Time: Day 1
HPO Nodes
HP:0002092: Pulmonary arterial hypertension
Genes 132
VPS33A LIFR SFTPA2 NKX2-1 IRF5 G6PC3 FGFR1 JAK2 ARHGAP31 AFF4 CAV1 HBB STAT1 FGFR3 KCNK3 LIPT1 GDF2 PAM16 FOXP1 TRNF MLX CAV1 SFTPC CHST3 IL12B COL1A1 GATA6 THPO MED25 HLA-DRB1 COX7B BANF1 HSPG2 SCARB2 SMAD4 MUC5B TERT ARHGAP31 NFIX ACVRL1 ND1 ND4 CCR6 NOTCH1 ATP5F1A CACNA1D COX1 ACVRL1 COLQ TRNW TRNQ ND5 SMAD9 HBB FIG4 ABCD4 GBA EIF2AK4 FBN1 HLA-DRB1 SLC37A4 ND6 MGP BSCL2 ALMS1 GBA KRAS DOCK6 BMPR2 MED12 FIG4 SLC25A24 CCN2 EOGT IRF5 COX3 CTCF FOXF1 HLA-B KIAA0319L SFTPB CAV1 NFIX KRT18 NOD2 DLL4 CAV1 VAC14 TCIRG1 COG1 IKBKG LAMA2 UBE2A PIGN COX2 GJA1 TNFSF11 FOXF1 RBPJ COL1A2 TRNS2 KRT8 SPECC1L SNX10 FOS PDSS1 SFTPB MPL CLCN7 SARS2 ENG CCR6 PPCS CACNA1D FLNA NOTCH1 AGPAT2 TBX4 GBA LAMB2 TRNS1 ACTA2 TRNL1 CCN2 PPARG NFU1 CAVIN1 IDUA TRNH BMPR2 PIGA LIPA SNP 0
Primary Outcomes
Description: To determine the prevalence of pulmonary hypertension and right ventricular load in patients with COVID-19 treated in intensive care unit evaluated by routine echocardiography.
Measure: Prevalence Time: Day 1